Search / 50 results found

  • Updated

BOSTON, Oct. 14, 2021 /PRNewswire/ -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today its first-in-class once-daily oral capsule AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), which was approved by the U.S. Food and Drug Administration (FDA) in March 2021, significantly reduced attention deficit hyperactivity disorder (ADHD) symptoms in children ages 6 to 12 years during a phase 3 controlled classroom clinical trial. The results are being presented in a poster and a Meet the Presenter session on October 15, 2021, during the American Psychiatric Nurses Association (APNA) 35th Annual Conference, held virtually on October 13-16.  AZSTARYS is the first and only medicine to add the innovative SDX prodrug with d-MPH.

  • Updated

BOSTON, Sept. 30, 2021 /PRNewswire/ -- Threats to employee wellbeing continue to intensify well over a year into the pandemic, as evidenced by a 21% rise in burnout and a 17% increase in somatic stress symptoms, a new meQuilibrium study found. The study examined changes in overall wellbeing among 5,474 meQuilibrium members from a broad range of industries representing managers and individual contributors.